Gene-based medicines for patients with serious diseases
CRISPR Therapeutics has raised €116M across 3 funding rounds from 12 investors, most recently a Series B round in Jun 2016. Based in Basel, Switzerland; founded 2013; active in Healthtech. Data as of 6 Aug 2026.
Timing: dormant vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.
| Date |
|---|
| Stage |
|---|
| Amount |
|---|
| Investors |
|---|
| 2016-06-01 | Series B | €35M | Clough Capital Partners,Franklin Templeton Investments,New Leaf Venture Partners,Wellington Management | View deal → |
| 2015-04-01 | Series B | €59M | Abingworth LLP,Bayer Global Investments,Celgene,GlaxoSmithKline,New Enterprise Associates,SR One+2 more | View deal → |
| 2014-04-01 | Series A | €23M | Versant Ventures | View deal → |
